UNIVERSAL FUSION EXPRESSION
DEAD

Serial Number

87364438

Owner

NEOGENOMICS LABORATORIES, INC.

Attorney

Anessa O. Kramer

First Use Date

Mar 30, 2017

Filing Date

Mar 9, 2017

Add to watchlist:

No watchlists yet
View on USPTO

UNIVERSAL FUSION EXPRESSION Trademark

Serial Number: 87364438 • Registration: 5699440

UNIVERSAL FUSION EXPRESSION is a trademark filed by NEOGENOMICS LABORATORIES, INC. on March 9, 2017. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

NEOGENOMICS LABORATORIES, INC. (84 trademarks)

12701 COMMONWEALTH DRIVE, SUITE 9
FORT MYERS, FL 33913

Entity Type: 03

Trademark Details

Filing Date

March 9, 2017

Registration Date

March 12, 2019

First Use Anywhere

March 30, 2017

First Use in Commerce

March 30, 2017

Cancellation Date

September 26, 2025

Goods & Services

Medical diagnostic testing services in the field of human disease and human medical conditions; medical testing for diagnostic or treatment purposes; providing medical information to others in the field of human disease, human medical conditions, medical diagnostic testing services and medical testing for diagnostic or treatment purposes; providing an Internet website portal featuring medical information in the field of human disease, and human medical conditions, medical diagnostic testing services, medical testing for diagnostic or treatment purposes; providing cloud-based medical information to others in the field of human disease, human medical conditions, medical diagnostic testing services, and medical testing for diagnostic or treatment purposes; medical testing for the detection of cancer; medical testing for the detection of genetic information pertaining to human disease; medical diagnostic testing to aid in diagnosis, prognosis and therapy selection; oncology reference laboratory testing services for diagnostic or treatment purposes

Genetic mapping for scientific purposes; genetic mapping for scientific purposes, namely, gene sequencing; medical research, namely, molecular sequencing; cancer study and analysis; clinical study and testing of cells for medical research purposes; medical and scientific research information in the field of gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells; scientific research in the field of gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells, and cancer; providing scientific and medical research information to others in the fields of oncology, pathology and gene sequencing, molecular sequencing, cancer study and analysis, and clinical study and testing of cells; scientific testing and research services and clinical scientific testing in the fields of oncology, pathology, gene sequencing, molecular sequencing, human disease and human medical conditions; providing an Internet website portal featuring scientific and medical research information in the field of gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells; scientific and medical research information in the fields of scientific testing and research services, medical research services, and clinical scientific testing; providing cloud-based scientific and medical research information to others in the field of scientific testing and research services, medical research services, and clinical scientific testing; providing temporary use of online non-downloadable software for analysis of medical test results; providing temporary use of online non-downloadable software for enhancement of analysis, research and review of information pertaining to medical, scientific and genetic testing and analysis, and for providing information pertaining to such testing and analysis; software as a service (SAAS) services featuring software for analysis of medical test results; software as a service (SAAS) featuring software for enhancement of analysis, research and review of information pertaining to medical, scientific and genetic testing and analysis, and for providing information pertaining to such testing and analysis; providing medical research and scientific research information in the field of oncology; scientific and medical research in the field of genetic testing, RNA testing and sequencing; scientific testing and research services in the field of human disease and human medical conditions; providing medical research services in the field of human disease and human medical conditions; providing clinical scientific testing services and medical research and testing for medical research services in the field of human disease and human medical conditions; clinical research laboratory services in the field of human disease, human medical conditions, and oncology reference laboratory services for medical research purposes; providing scientific and medical research information, interactive information, and reports to others in the fields of pathology, diagnostic testing and oncology testing

Filing History

CANCELLED SEC. 8 (6-YR)
Sep 26, 2025 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 12, 2024 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 1, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 1, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 1, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 1, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 1, 2023 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 10, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 10, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 10, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 10, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 10, 2022 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 13, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 13, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 13, 2022 REAP
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 3, 2019 ASCK
REGISTERED-SUPPLEMENTAL REGISTER
Mar 12, 2019 R.SR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 6, 2019 PREV
ASSIGNED TO LIE
Feb 5, 2019 ALIE
EXPARTE APPEAL TERMINATED
Jan 29, 2019 EXPT
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Jan 29, 2019 CNTA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 26, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 25, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 25, 2019 TROA
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Aug 7, 2018 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Aug 7, 2018 GEAP
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Aug 7, 2018 EPEN
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Aug 7, 2018 CPEA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Aug 7, 2018 AAUA
USE AMENDMENT ACCEPTED
Aug 6, 2018 IUAA
EX PARTE APPEAL-INSTITUTED
Jul 18, 2018 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jul 18, 2018 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Jul 18, 2018 EXAF
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 14, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 14, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 12, 2018 ERFR
AMENDMENT TO USE PROCESSING COMPLETE
Jul 12, 2018 AUPC
USE AMENDMENT FILED
Jul 12, 2018 IUAF
TEAS AMENDMENT OF USE RECEIVED
Jul 11, 2018 EAAU
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 18, 2018 GNFN
FINAL REFUSAL E-MAILED
Jan 18, 2018 GNFR
FINAL REFUSAL WRITTEN
Jan 18, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 27, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 27, 2017 CRFA
ASSIGNED TO LIE
Dec 21, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 13, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 13, 2017 GNRN
NON-FINAL ACTION E-MAILED
Jun 13, 2017 GNRT
NON-FINAL ACTION WRITTEN
Jun 13, 2017 CNRT
ASSIGNED TO EXAMINER
Jun 4, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 14, 2017 NWOS
NEW APPLICATION ENTERED
Mar 13, 2017 NWAP